Subcutaneous hormone implants are currently unavailable whilst the Medicines and Healthcare products Regulatory Agency (MHRA) undertakes a review.
Until recently, these implants were available from a small number of specialist centres in the UK. The British Menopause Society (BMS) feels strongly that they remain an important treatment option for women who fail to respond to standard delivery routes.
BMS Chair, Professor Janice Rymer, has written to the MHRA requesting specific information about the reasons for their actions to restrict the supply of subcutaneous hormone implants, asking for an indication as to when the supply situation will be resolved. A response from the MHRA is yet to be received.
An update will be published on the BMS website as further information becomes available.
Related BMS news items:
Subcutaneous Hormone Implant Therapy, 20 March 2024
Update – Subcutaneous Hormone Implant Therapy, 02 April 2024